2026-01-13 - Analysis Report
**Summary Report: Eli Lilly and Co (LLY)**

**Company Overview**
Eli Lilly and Co is a pharmaceutical and healthcare company.

**Return Comparison (LLY vs S&P 500 VOO)**

* Cumulative Return (LLY): 281.90%
* Cumulative Return (VOO): 94.34%
* Degree of Divergence (as of last day of data): 181.70
* Relative Divergence: 80.50%

**Alpha-Beta Analysis**

| Year | CAGR | MDD | Alpha | Beta | Market Cap |
|------|------|-----|-------|-------|-----------|
| 2016-2018 | 37.0% | 14.3% | 33.0% | 0.7 | 103.7B |
| 2017-2019 | 36.0% | 14.7% | 19.0% | 0.7 | 117.8B |
| 2018-2020 | 30.0% | 20.9% | 10.0% | 0.7 | 151.4B |
| 2019-2021 | 49.0% | 20.9% | 5.0% | 0.7 | 247.6B |
| 2020-2022 | 59.0% | 20.9% | 60.0% | 0.7 | 328.0B |
| 2021-2023 | 116.0% | 18.0% | 115.0% | 0.5 | 522.6B |
| 2022-2024 | 123.0% | 27.0% | 104.0% | 0.6 | 692.1B |
| 2023-2025 | 183.0% | 29.9% | 121.0% | 0.7 | 963.4B |

**Recent Stock Price Fluctuations**

* 5-day SMA: $1,080.38
* 20-day SMA: $1,068.69
* 60-day SMA: $992.54
* Last Market Price: $1,081.00
* Change from Previous Close: 1.64%

**RSI, PPO, and Delta Analysis**

* Market Risk Indicator (MRI): 0.80
* RSI: 52.44
* PPO: -0.29
* Hybrid Signal: Buy (Cash 0%)
* Risk Level: Medium (MRI 0.80)
* Recent (20 days) relative divergence change: -3.40 (worsening)
* 7-day Rank change: 0 (flat)
* 7-day Dynamic Expected Return change: 4.80 (+) improving
* Expected Return (%): 52.10%
* Expected excess return compared to S&P 500 if invested long-term: (link)

**Recent News & Significant Events (Yahoo Finance)**

* [2026-01-12] Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2026-2030 (Jan 2026) - 24/7 Wall St. (link)
* [2026-01-09] Eli Lilly Stock Broke Out Following Plan To Acquire Ventyx Biosciences - Investor's Business Daily (link)
* [2026-01-12] This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. - Barron's (link)
* [2026-01-12] Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts - MSN (link)
* [2026-01-11] This Healthcare Stock Could Be One of the Best Companies to Own in 2026 - The Motley Fool (link)
* [2026-01-09] Eli Lilly vs. Novo Nordisk: Which Is the Best Stock to Buy Today? - Morningstar (link)

**Analyst Opinions**

* Analyst Consensus:
 - Key: Buy
 - Mean (1=StrongBuy~5=Sell): 1.70 (~Buy)
 - Opinions: 27
 - Target Price (avg/high/low): 1116.33 / 1500.00 / 770.00

**Recent Earnings Analysis**

| Date | EPS | Revenue |
|------|-----|---------|
| 2025-10-30 | 6.22 | $17.60B |
| 2025-08-07 | 6.3 | $15.56B |
| 2025-05-01 | 3.07 | $12.73B |
| 2024-10-30 | 1.08 | $11.44B |
| 2025-10-30 | 1.08 | $11.44B |

**Quarterly Revenue and Profitability Analysis**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $17.60B | 82.91% |
| 2025-06-30 | $15.56B | 84.27% |
| 2025-03-31 | $12.73B | 82.53% |
| 2024-12-31 | $13.53B | 82.24% |
| 2024-09-30 | $11.44B | 81.02% |

**Quarterly Capital and Profitability Analysis**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $23.79B | 23.46% |
| 2025-06-30 | $18.27B | 30.98% |
| 2025-03-31 | $15.76B | 17.50% |
| 2024-12-31 | $14.19B | 31.07% |
| 2024-09-30 | $14.24B | 6.81% |

**Comprehensive Analysis (Summary)**

Based on the provided data, Eli Lilly and Co has shown significant growth in its cumulative return, especially when compared to the S&P 500 VOO. The company's Alpha-Beta analysis indicates a consistent return on investment, with a significant increase in market capitalization. However, the recent relative divergence change indicates a decline, which may be a cause for concern. The stock price fluctuations also indicate a short-term market correction. The RSI, PPO, and Delta analysis suggest a neutral risk indicator, but the expected return is high. The recent news and events indicate significant market activities and potential future directions. The analyst opinions suggest a buy consensus with a high target price.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.